Is progression-free survival a more relevant endpoint than overall survival in first-line HR+/HER2− metastatic breast cancer?

References

• National Cancer InstituteSEER Cancer Stat Facts: Female Breast Cancer Available from: http://seer.cancer.gov/statfacts/html/breast.htmlAccessed March 29, 2018
   Google Scholar
• SiegelRLMillerKDJemalACancer statistics, 2016CA Cancer J Clin201666173026742998
   PubMed Web of Science ®Google Scholar
• ClemonsMDansonSHamiltonTGossPLocoregionally recurrent breast cancer: incidence, risk factors and survivalCancer Treat Rev2001272678211319846
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsLancet20053659472168771715894097
   PubMed Web of Science ®Google Scholar
• MartinoMBallestreroAZambelliALong-term survival in patients with metastatic breast cancer receiving intensified chemotherapy and stem cell rescue: data from the Italian registryBone Marrow Transplant201348341441822863724
   PubMed Web of Science ®Google Scholar
• VisovskyCTreatment considerations for the management of patients with hormone receptor-positive metastatic breast cancerJ Adv Pract Oncol20145532133026114012
   PubMedGoogle Scholar
• American Cancer SocietyBreast Cancer Facts & FiguresAtlantaAmerican Cancer Society2015
   Google Scholar
• ReinertTBarriosCHDefinition of first-line endocrine therapy for hormone receptor-positive advanced breast cancerJ Clin Oncol201634161959156027001564
   PubMed Web of Science ®Google Scholar
• National Cancer InstituteBreast Cancer Treatment (PDQ®) – Health Professional Version Available from: https://www.cancer.gov/types/breast/hp/breast-treatment-pdqAccessed March 29, 2018
   Google Scholar
• Gonzalez-AnguloAMMorales-VasquezFHortobagyiGNOverview of resistance to systemic therapy in patients with breast cancerAdv Exp Med Biol200760812217993229
   PubMed Web of Science ®Google Scholar
• JohnstonSRNew strategies in estrogen receptor-positive breast cancerClin Cancer Res20101671979198720332324
   PubMed Web of Science ®Google Scholar
• BaselgaJCamponeMPiccartMEverolimus in postmenopausal hormone-receptor-positive advanced breast cancerN Engl J Med2012366652052922149876
   PubMed Web of Science ®Google Scholar
• FinnRSCrownJPLangIThe cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole vs. letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 studyLancet Oncol2015161253525524798
   PubMed Web of Science ®Google Scholar
• HortobagyiGNStemmerSMBurrisHARibociclib as first-line therapy for HR-positive, advanced breast cancerN Engl J Med2016375181738174827717303
   PubMed Web of Science ®Google Scholar
• MoherDLiberatiATetzlaffJAltmanDGGroup PPreferred reporting items for systematic reviews and meta-analyses: the PRISMA statementPLoS Med200967e100009719621072
   PubMed Web of Science ®Google Scholar
• BachelotTBourgierCCropetCRandomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO studyJ Clin Oncol201230222718272422565002
   PubMed Web of Science ®Google Scholar
• MartinMLoiblSvon MinckwitzGPhase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) studyJ Clin Oncol20153391045105225691671
   PubMed Web of Science ®Google Scholar
• MehtaRSBarlowWEAlbainKSCombination and fulvestrant in metastatic breast cancerN Engl J Med2012367543534422853014
   PubMed Web of Science ®Google Scholar
• JohnstonSRKilburnLSEllisPFulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trialLancet Oncol2013141098999823902874
   PubMed Web of Science ®Google Scholar
• DicklerMNBarryWTCirrincioneCTPhase III trial evaluating letrozole as first-line endocrine therapy with or without bevacizumab for the treatment of postmenopausal women with hormone receptor-positive advanced-stage breast cancer: CALGB 40503 (Alliance)J Clin Oncol201634222602260927138575
   PubMed Web of Science ®Google Scholar
• ParkIHLeeKSRoJEffects of second and subsequent lines of chemotherapy for metastatic breast cancerClin Breast Cancer2015151e55e6225445418
   PubMedGoogle Scholar
• EllisMJLlombart-CussacAFeltlDFulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: overall survival analysis from the phase II FIRST studyJ Clin Oncol201533323781378726371134
   PubMed Web of Science ®Google Scholar
• GligorovJDovalDBinesJMaintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trialLancet Oncol201415121351136025273343
   PubMed Web of Science ®Google Scholar
• LamSWde GrootSMHonkoopAHPaclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a multicentre, open-label, randomised phase 2 trialEur J Cancer201450183077308825459393
   PubMed Web of Science ®Google Scholar
• NielsenDLBjerreKDJakobsenEHGemcitabine plus docetaxel versus docetaxel in patients with predominantly human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: a randomized, phase III study by the Danish Breast Cancer Cooperative GroupJ Clin Oncol201129364748475422084374
   PubMed Web of Science ®Google Scholar
• TwelvesCAwadaACortesJSubgroup analyses from a phase 3, open-label, randomized study of eribulin mesylate versus capecitabine in pretreated patients with advanced or metastatic breast cancerBreast Cancer (Auckl)201610778427398025
   PubMed Web of Science ®Google Scholar
• TwelvesCCortesJVahdatLEfficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studiesBreast Cancer Res Treat2014148355356125381136
   PubMed Web of Science ®Google Scholar
• WeltAMarschnerNLerchenmuellerCCapecitabine and bevacizumab with or without vinorelbine in first-line treatment of HER2/neu-negative metastatic or locally advanced breast cancer: final efficacy and safety data of the randomised, open-label superiority phase 3 CARIN trialBreast Cancer Res Treat201615619710726927446
   PubMed Web of Science ®Google Scholar
• ZielinskiCLangIInbarMBevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trialLancet Oncol20161791230123927501767
   PubMed Web of Science ®Google Scholar
• LuckHJLubbeKReinischMPhase III study on efficacy of taxanes plus bevacizumab with or without capecitabine as first-line chemotherapy in metastatic breast cancerBreast Cancer Res Treat2015149114114925519041
   PubMed Web of Science ®Google Scholar
• MacalaladARHaoYLinPLTreatment patterns and duration in post-menopausal women with HR+/HER2-metastatic breast cancer in the US: a retrospective chart review in community oncology practices (2004-2010)Curr Med Res Opin201531226327325350226
   PubMed Web of Science ®Google Scholar
• FukudaTShiroiwaTShimozumaKLong-term Eq-5d score for patients with metastatic breast cancer; comparison of first-line oral S-1 and taxane therapies in the randomized “select” trialValue Health2015187A467
   PubMed Web of Science ®Google Scholar
• VermaSO’ShaughnessyJBurrisHAHealth-related quality of life of postmenopausal women with hormone receptor–positive, HER2-advanced breast cancer treated with ribociclib + letrozole: Results from MONALEESA-2J Clin Oncol20173531 Suppl133
   Web of Science ®Google Scholar
• CANCERMPACTMore Than Just NumbersNew York City, NY, USAKantar Health2016
   Google Scholar